Reports

224 Results (Page 2 of 9)

Australia Markets Research Reports

Digital Health

Australia Blockchain Technology in Healthcare Market Analysis

This report presents a strategic analysis of the Australia Blockchain Technology in Healthcare Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Blockchain Technology in Healthcare Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Pharmaceuticals

Australia Oncology Therapeutics Market Analysis

By 2030, it is anticipated that the Australia Oncology Therapeutics Market will reach a value of $4.6 Bn from $2.2 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030. The Oncology Therapeutics Market in Australia is dominated by a few domestic pharmaceutical companies such as CSL Behring, Mesoblast, and Sirtex Medical. The Oncology Therapeutics Market in Australia is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for Australia Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Medical Devices

Australia Neurology Devices Market Analysis

Australia Neurology Device Market size is at around $151.44 Mn in 2022 and is projected to reach $308.46 Mn in 2030, exhibiting a CAGR of 9.3% during the forecast period. Australia is a major importer of neurology devices and suffers from a major burden of neurology diseases the market is well-captured by players like Medtronics, BHP Group, Rio Tinto, and Westpac. This report by Insights10 is segmented by product type like neurostimulation, interventional neurology, neurosurgery devices, and neuro-endoscopes, and by the end user.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Hereditary Angioedema Therapeutics Market Analysis

Australia Hereditary Angioedema Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. The regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis

Australia Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Healthcare Services

Australia Dental Care Market Analysis

The Australia dental care market is projected to grow from $431 Mn in 2022 to $791 Mn by 2030, registering a CAGR of 7.9% during the forecast period of 2022-2030. The aging population and rising demand for cosmetic dental procedures are two factors that will likely cause the market to expand in the upcoming years. Pacific Smiles Group, Plena Healthcare, and Nurture Dental are a few of the major players in the Australian dental care market.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis

Australia Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Digital Health

Australia Telemedicine Market Analysis

Telemedicine is a sector of immense growth potential with a market size of about $730 Mn in 2022 with a CAGR of about 19.7% and is expected to grow to $3,075 Mn in 2030 as predicted by Insights10 report on the Australia Telemedicine Market Analysis. The inclusion of telemedicine services by general practitioners and telemedicine coverage in Medicare Australia are major growth drivers. The market is segmented by component, modality, application, and end user. Doxy.me Inc. and Teladoc Health are major market players in telemedicine.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Angelman Syndrome Therapeutics Market Analysis

Australia During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Pharmaceuticals

Australia Pharmaceutical Market Analysis

This report presents a strategic analysis of the Australia Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Pharmaceutical Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia ATTR (Transthyretin Amyloidosis) Therapeutics Market Analysis

Australia ATTR (Transthyretin Amyloidosis) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An rare and progressive condition known as ATTR (Transthyretin Amyloidosis) is characterised by the buildup of aberrant proteins in the body, including misTTR. The market for treatments for transthyretin amyloidosis is primarily driven by the expansion of the population and the availability of favourable reimbursement programmes. The market is predicted to increase as a result of strategic actions done by major players such raising knowledge of the target conditions like ATTR and the long-term advantages of treatments that are currently accessible. The market for treating transthyretin amyloidosis is currently constrained by a number of factors, including low awareness of the condition in developing nations, misdiagnosis of the condition, high costs of disease diagnosis and treatment, the lack of adequate clinical trials, and the absence of effective medications. Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Alnylam Pharmaceuticals, BridgeBio Pharma, Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech, and numerous others are global competitors in the ATTR (Transthyretin Amyloidosis) market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia MPS-III (Sanfilippo Syndrome) Drugs Market Analysis

Australia MPS-III (Sanfilippo Syndrome) drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for MPS-III (Sanfilippo Syndrome) drugs is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global MPS-III (Sanfilippo Syndrome) drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Mucopolysaccharidosis I (MPS-I) Drugs Market Analysis

Australia Mucopolysaccharidosis I (MPS-I) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in Mucopolysaccharidosis I (MPS-I) Drugs Market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Drugs, Abeona Drugs, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Drugs, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Medical Devices

Australia Medical Devices Market Analysis

This report presents a strategic analysis of the Australia Medical Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Medical Devices Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Charcot-Marie-Tooth Disease (CMT) Therapeutics Market Analysis

Australia Charcot-Marie-Tooth Disease (CMT) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The majority of hereditary peripheral neuropathies are Charcot-Marie-Tooth (CMT) illness, commonly referred to as hereditary motor and sensory neuropathy (HMSN). Genes that support or generate proteins important in the construction and operation of the myelin sheath or the peripheral nerve axon are mutated, leading to CMT. An increase in genetic illnesses will result in more innovations being made in this area, which will enhance market growth because there are many genes that cause these problems. The above-mentioned forecast period will witness the emergence of the market for Charcot Marie-Tooth disease due to multiple prospects that will be heightened by the rising focus on targeted therapies and the favorable government regulations. Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp., Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc. are some of the major players in the Charcot Marie Tooth Disease Market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Herpes Simplex Virus Therapeutics Market Analysis

Australia Herpes Simplex Virus Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Herpes simplex virus (HSV) is a common viral infection that can cause a range of diseases in humans. High Prevalence of HSV Infections, Increasing Awareness and Diagnosis, Continued research and development efforts, Technological advancements and Increasing healthcare expenditure, particularly in developed countries, provides a supportive environment for the growth of the HSV Therapeutics market. Social stigma surrounding herpes, Drug-resistant HSV strains provided by limited treatment options are restraining factors in herpes simplex therapeutics market. GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd. Are global key players in herpes simplex therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Medical Devices

Australia Cardiac Monitoring Devices Market Analysis

This report presents a strategic analysis of the Australia Cardiac Monitoring Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Australia Cardiac Monitoring Devices Market, offering unmatched value, accuracy and expert insights.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Adrenoleukodystrophy (ALD) Therapeutics Market Analysis

Australia Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Australia Adrenoleukodystrophy (ALD) drugs market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Batten's Disease (CLN-2) Therapeutics Market Analysis

Australia Batten?s Disease (CLN-2) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neuronal Ceroid Lipofuscinosis (NCL), often known as Batten disease, is a rare and severe autosomal recessive neurodegenerative lysosomal storage condition brought on by cellular buildup of aberrant auto-fluorescent lipoproteins (lipofuscin). Seizures and a progressive loss of movement, verbal, visual, and cognitive abilities are features of this neurodegenerative condition that primarily affects the nerve system. Research advancements in nanotechnology could result in the creation of fresh therapies that would benefit persons who suffer from this ailment. Additionally, it is a paediatric brain condition that is extremely rare yet progresses quickly. As a result, Batten's Disease may be exacerbated by the predicted rising prevalence of disease. Therapeutics market (CLN-2). The market for Batten's Disease (CLN-2) Therapeutics is constrained by a lack of treatment and symptoms that are challenging to identify. Regenxbio, Polaryx Therapeutics and Abeona Therapeutics are some of the key players in the market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Pharmaceuticals

Australia Primary Hyperoxaluria (PH) Drugs Market Analysis

Australia Primary Hyperoxaluria (PH) drugs market is expected to grow from $2.1 Mn in 2022 to $8.8 Mn in 2030 with a CAGR of 19% for the year 2022-2030 due to the number of clinical trials including innovative therapeutic assets being investigated at various stages of development has increased in Australia and also new approaches being developed in genetic engineering for the treatment of PH. The market is segmented by type, diagnosis, drug, treatment, and by distribution channel. Some of the key competitors in Australia's primary hyperoxaluria market are Allena Pharmaceuticals, Alnylam Pharmaceuticals, and Amarna Therapeutics.

PUBLISHED: Mar, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Primary Hyperoxaluria (PH) Drugs Market Analysis

Australia Primary Hyperoxaluria (PH) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Unmet Medical Need, Increasing Awareness and Diagnosis, Advancements in Research and Development, Growing Investment and Pipeline Development, Collaboration and Patient Advocacy,rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Drugs Market are Allena Pharmaceuticals, Inc., Intellia Drugs, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Healthcare Services

Australia Home Healthcare Market Analysis

Australia's home healthcare market is projected to grow from $4.3 Bn in 2022 to $8.9 Bn by 2030, registering a CAGR of 9.43% during the forecast period of 2022-30. Because of the rising older population and the increasing number of people motivated to fight ailments including heart problems, diabetes, and various respiratory illnesses, the Australian home healthcare market is expanding at a promising CAGR. The market is segmented by solution, by deployment, and by end-use. There are a number of private companies that provide home healthcare services in Australia, including Bupa, NIB Health Funds, and HCF.

PUBLISHED: Nov, 2022 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Sanfilippo Syndrome (MPS-III) Therapeutics Market Analysis

Australia Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Interstitial Cystitis Therapeutics Market Analysis

Australia Interstitial Cystitis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 30. The global market is expanding as a result of a rise in the frequency of interstitial cystitis and support for research. Major global players in this market are Amneal Pharmaceuticals Inc, Astellas Pharma Inc, Aurobindo Pharma Ltd, Bayer AG, Cadila Healthcare Ltd, Eli Lilly and Co, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd, Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd, Mission Pharmacal Co, Perrigo Co. Plc, Pfizer Inc, Purdue Pharma LP, Seikagaku Corp, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc.

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

Rare Diseases

Australia Multiple Sclerosis Therapeutics Market Analysis

Australia multiple sclerosis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence of multiple sclerosis (MS) is rising, and funding for MS research is rising as well. These are the two reasons propelling market expansion. Major global players in this market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Mylan N.V. (U.S.)

PUBLISHED: Jul, 2023 | FORMAT: PPT | LAST UPDATED: May, 2024 | PRICE: $3999

subscribe to our newsletter
up